HCW Biologics has exercised its option to regain full ex vivo rights to two commercial-ready reagents, HCW9206 and HCW9201, from Wugen Inc. These reagents are designed to improve CAR-T cell production by reducing costs and enhancing therapeutic effectiveness, particularly by enriching long-lived T-memory stem cells that improve treatment durability. The company plans to commercialize these reagents through partnerships with firms focused on CAR-T and NK-cell therapies, potentially advancing treatments for blood cancer, solid tumors, and autoimmune diseases. Recent studies published in reputable journals support the potential of HCW9206 to improve CAR-T therapy outcomes and manufacturing efficiency.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
